Medicure (CVE:MPH) Reaches New 1-Year High – Here’s What Happened

Shares of Medicure Inc. (CVE:MPH) reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as C$4.95 and last traded at C$4.36, with a volume of 5,760 shares changing hands. The stock had previously closed at C$2.98.

Medicure Price Performance

The company has a 50 day moving average of C$2.32 and a 200-day moving average of C$1.57. The stock has a market capitalization of C$44.56 million, a P/E ratio of -5.93 and a beta of 0.98. The company has a quick ratio of 1.28, a current ratio of 0.97 and a debt-to-equity ratio of 6.02.

Medicure Company Profile

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.